BioSpace News Archive

Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association Clinical & Scientific Conference later this week.

Sensus Healthcare, Inc. announces that management will be presenting at the following investment conferences during March.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32nd Annual Oppenheimer Healthcare Conference at 6:20 a.m. PT on Wednesday, March 16, 2022.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum, which takes place March 22-23, 2022.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and twelve months ended December 31, 2021.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported financial results for the quarter and full-year ended December 31, 2021 and highlighted recent corporate progress.

BioVie Inc. announced the participation of its management team in a presentation and one-on-one investor meetings at the Oppenheimer Virtual Annual Healthcare Conference, to be held March 15-17, 2022.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced its participation in the following investor conferences.

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation for Intellia’s ex vivo investigational T cell receptor -T cell therapy, NTLA-5001, for the treatment of acute myeloid leukemia.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, March 23, 2022.